Clinical trials: Tislelizumab, open to volunteers
NSCLC
Safety and Efficacy of NK510 to Treat NSCLC
This study assesses the safety and efficacy of NK510 combined with PD-(L)1 inhibitors for relapsed/refractory advanced NSCLC, with two administration routes: intravenous infusion and intrapleural perfusion for malignant pleural…
- Trial name
- NCT06097962
- Testing
- NK510, Tislelizumab，atezolizumab or sugemalimab, systemic therapy as selected by the investigator
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Base Therapeutics (Shanghai) Co., Ltd.
NSCLC
Multimodal Ablation Combined With Perioperative Tislelizumab and Chemotherapy for Resectable II-IIIB NSCLC
This is a prospective, open-label, single-center, single-arm phase II clinical trial evaluating the efficacy and safety of multimodal ablation in combination with perioperative tislelizumab and chemotherapy in patients with…
- Trial name
- NCT07729670
- Testing
- Multimodal Ablation, Neoadjuvant therapy, Surgery
- Volunteers
- 42 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Gastric Cancer
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
This study is a single-center, prospective, phase II clinical trial aimed at assessing the impact of HIPEC combined with systemic chemotherapy and immune checkpoint inhibitors on the R0 resection rate in patients with peritoneal…
- Trial name
- NCT06685887
- Testing
- HIPEC, SOX, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Esophageal Squamous Cell Carcinoma
Low-dose Radiation Combined With Neoadjuvant Immunochemotherapy for Esophageal Squamous Cell Carcinoma
This study aims to investigate the efficacy and safety of low-dose radiation combined with neoadjuvant chemotherapy and immunotherapy in the treatment of locally advanced thoracic esophageal squamous cell carcinoma.
- Trial name
- NCT06446726
- Testing
- Tislelizumab, Low-dose radiotherapy, Nab-paclitaxel
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Advanced Solid Tumour
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
An Open-label, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of LBL-024 in Combination With Other Drugs for the Treatment of Patients With Advanced Solid Tumour.
- Trial name
- NCT07331155
- Testing
- LBL-024 for Injection, Cisplatin Injection, Paclitaxel Injection
- Where
- 7 sites in China
- Volunteers
- 110 people
- Sponsor
- Nanjing Leads Biolabs Co.,Ltd
Hepatocellular Carcinoma (HCC)
Lenvatinib Plus Tislelizumab With or Without Gefitinib for Advanced Liver Cancer
This study is for people with unresectable or advanced hepatocellular carcinoma who have not received previous systemic treatment for liver cancer. The study will compare lenvatinib plus tislelizumab with or without gefitinib.
- Trial name
- LENTIG-HCC (NCT07829926)
- Testing
- Lenvatinib, Tislelizumab, Gefitinib
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Solid Tumor
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with…
- Trial name
- NCT06349837
- Testing
- Tislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan University
Soft Tissue Sarcomas, Angiosarcoma
IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)
This study will enroll patients with specific subtypes of unresectable or metastatic soft tissue sarcoma, and will combine tislelizumab with the standard chemotherapy of liposomal doxorubicin and ifosfamide to initially explore…
- Conditions
- Soft Tissue Sarcomas, Angiosarcoma, Fibrosarcoma, Leiomyosarcoma
- Trial name
- TAIS (NCT06849986)
- Testing
- Tislelizumab+liposomal doxorubicin+ifosfamide
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Fudan University
Carcinoma, Hepatocellular, Liver Cell Carcinoma
Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma
The investigators hypothesize that the addition of Tislelizumab after definitive local therapy for locally advanced inoperable Hepatocellular carcinoma (HCC) will synergize with local therapy as well as treat micro metastatic…
- Trial name
- NCT05366829
- Testing
- Tislelizumab
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Rutgers, The State University of New Jersey
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS
The efficiency and safety of PD-1 inhibitor in combination with venetoclax and hypomethylation agent in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndrome remain uncertain.
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes, Minimal Residual Disease
- Trial name
- NCT06536959
- Testing
- PD-1 inhibitor, Venetoclax, Decitabine, Azacytidine
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Beijing 302 Hospital
Rectal Cancer
Modified Short-Course Radiotherapy Combined With Tislelizumab and CAPOX for pMMR/MSS Rectal Cancer
The goal of this clinical trial is to learn if node-sparing modified short-course radiotherapy combined with tislelizumab and CAPOX works to treat pMMR/MSS locally advanced mid-to-low rectal cancer.
- Trial name
- mRCATS (NCT07900061)
- Testing
- node-sparing modified short-course radiotherapy, standard short-course radiotherapy
- Volunteers
- 210 people
- Sponsor
- Sir Run Run Shaw Hospital
Metastatic Colorectal Cancer
- IKF/AIO-QUINTIS - Evaluating Fruquintinib in Combination With Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer Without Active Liver Metastases
This is a prospective, randomized, open-label, multicenter phase II investigating the therapy of Fruquintinib in combination with Tislelizumab in patients with MSS/pMMR metastatic colorectal cancer without liver metastases.
- Trial name
- NCT06856837
- Testing
- Fruquintinib, Tislelizumab, Trifluridine/tipiracil
- Where
- 23 sites in Austria, Germany
- Volunteers
- 140 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
This study is a multiple cohort, multicenter, open-label Phase 1 study with dose-escalation substudies investigating intravenous (IV) BAL0891 as monotherapy, and in combination with tislelizumab or paclitaxel, to determine the…
- Conditions
- Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
- Trial name
- NCT05768932
- Testing
- BAL0891, Tislelizumab, Paclitaxel
- Where
- 17 sites in United States, South Korea
- Volunteers
- 260 people
- Sponsor
- SillaJen, Inc.
Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric…
- Trial name
- NCT07043400
- Testing
- Subcutaneous Tislelizumab, Intravenous Tislelizumab, Cisplatin
- Where
- 95 sites in United States, Argentina and 14 more
- Volunteers
- 351 people
- Sponsor
- BeOne Medicines
Metastatic Nasopharyngeal Carcinoma, Intermittent Systematic Chemotherapy
Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma
This study aimed to investigate the value of a novel strategy of intermittent systematic chemotherapy (ISC) in widely metastatic nasopharyngeal carcinoma (wmNPC) patients who achieve objective response after systematic…
- Trial name
- NCT06331845
- Testing
- Gemcitabine, Cisplatin, Paclitaxel protein-bound
- Volunteers
- 39 people
- Sponsor
- Fujian Cancer Hospital
Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
There have been initial explorations on the treatment of peritoneal metastasis of gastric and colorectal cancer both at home and abroad.
- Trial name
- TRIUNITE06 (NCT07453875)
- Testing
- LDRT, SOX or CAPOX regimen, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
NSCLC (Advanced Non-small Cell Lung Cancer)
A Retrospective Real-World Study Based on RATIONALE-307
The study aims to retrospectively collect long-term survival data from patients who received first-line tislelizumab combined with chemotherapy in the RATIONALE-307 trial, in order to enrich the evidence on long-term benefits in…
- Trial name
- NCT07478809
- Testing
- No intervention
- Where
- China
- Volunteers
- 109 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Lung Cancer, Non-small Cell Lung Cancer
Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer
This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
- Trial name
- NCT06877299
- Testing
- Low-Dose Radiation(LDRT) + Stereotactic body radiotherapy (SBRT)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
HCC - Hepatocellular Carcinoma, TP53 Gene Mutation
A Clinical Trial of Firsekibart, Tislelizumab, and Lenvatinib in Patients With Unresectable, TP53-Mutated Hepatocellular Carcinoma
This study aims to evaluate the effectiveness and safety of a combination therapy with Fuxinqibai monoclonal antibody, Tislelizumab, and Lenvatinib in patients with advanced, unresectable TP53-mutated hepatocellular carcinoma…
- Conditions
- HCC - Hepatocellular Carcinoma, TP53 Gene Mutation, Unresectable, Resistant Cancer
- Trial name
- NCT07535840
- Testing
- Firsekibart + Tislelizumab + Lenvatinib
- Volunteers
- 25 people
- Sponsor
- Tongji Hospital